The CNS recruitment partner that delivers when timelines collapse

Across 140+ studies and Phase 3 work in Alzheimer's, ALS, schizophrenia, bipolar and depression, Leapcure recruits the CNS patients protocols require, then pre-screens every referral so sites enroll faster.

Talk to our CNS teamSee how it works →
50%+
Of site enrollments, averaged since 2020
across our portfolio
140+
Studies across 40+ sponsors
1,600+ sites, 45+ countries
~3x
Outperformance vs. other vendors
on a Phase 3 MDD study
~$1.6M
Saved across two Phase 3 CNS programs
Alzheimer's and ALS

Understanding CNS Recruitment Across Psychiatry and Neurology

CNS spans psychiatry (MDD, bipolar, schizophrenia, insomnia) and neurology (Alzheimer's, ALS, and adjacent indications). These are among the hardest cohorts to find and enroll, from adolescent schizophrenia and treatment-resistant depression to rural sleep studies with overnight stays, and competitive neurodegenerative landscapes where timelines often collapse.

CNS recruitment is hard for structural reasons. Many psychiatry protocols require scale-validation (MADRS and similar instruments), screen-fail risk is high, stigma and hesitancy keep eligible patients out of view, and sponsors compete for the same small pools of patients. Volume vendors respond by flooding sites with people who fail screening, which spends scarce coordinator time and slows enrollment instead of accelerating it.

Leapcure works differently. Across 140+ studies we have averaged more than half of every site's enrollments since 2020. Our Phase 3 CNS wins cut timelines from months to weeks, saved clients roughly $500K and $1.1M, and outperformed every other vendor on a Phase 3 depression study by about 3x. We blend advocacy, precision digital, and physician outreach, then pre-screen every referral (including MADRS and similar scale validation) so the patients who reach a site are eligible, prepared, and ready to enroll faster.

The Challenge

CNS trials stall for predictable reasons: the hardest cohorts are difficult to find, timelines collapse without warning, scale validation adds screening burden, and volume vendors flood sites with patients who fail screening. Leapcure is built to solve each one.

The hard CNS cohorts most vendors cannot find

Adolescent schizophrenia, treatment-resistant depression, bipolar, and rare neurodegenerative cohorts sit in small, dispersed, often hesitant populations. Generic outreach barely reaches them, so sponsors are left short on exactly the patients a protocol depends on most.

Adolescent schizophrenia (Phase 3, US): Leapcure delivered 50% of all patients enrolled. Bipolar (Phase 3, US, advocacy-only): 15 of the final 30 patients enrolled came from Leapcure.

Timelines collapse and studies need speed

CNS programs routinely lose months to slow startup or competitive enrollment, then have to make it up in weeks. Most recruiters cannot surge on demand, so the timeline keeps slipping while sites wait for qualified patients.

A sleep and mental-health device study (single site, Canada) hit the 90+ patient enrollment target in one week against an expected timeline of over two months. A depression and insomnia Phase 3 registered hundreds of patients and enrolled about 15 in a 1-2 week window against a planned four-month period.

Scale validation and screening burden (MADRS and similar)

Psychiatry protocols often require scale validation such as MADRS before a patient counts as eligible. Unvalidated referrals turn into screen fails and wasted rater time. Confirming scores before referral is what keeps screening efficient.

MedOps pre-screening validated patient MADRS scores. A Phase 1 CNS funnel: 1,228 referred, 1,040 reached, 85 assigned, 30 screened, 9 enrolled (10% of total study enrollments), with 25-30 additional expected on need.

Volume vendors flood sites with unqualified referrals

The common model is to push raw referral volume and let sites sort through the failures. In CNS, that buries coordinators and depresses screening and enrollment rates. Sponsors should ask how much enrollment a partner actually carries, not how many referrals they generate.

On a Phase 3 MDD study, Leapcure outperformed all other vendors by about 3x, doubled site-contacted rates, tripled screening and enrollment rates, and was the only source of enrollments at eight sites.

How Leapcure recruits CNS patients across psychiatry and neurology

We activate the channels CNS patients trust, pre-screen every referral (including MADRS and similar scale validation) before any site sees it, then deliver and de-risk continuously so enrollment holds even when timelines collapse.

1

Activate advocacy, precision digital, and physician outreach

We engage national mental-health and neurology advocacy partners, run precision digital (including Reddit) mapped to your eligibility and geographies, and add physician outreach, all adapted to each site's capacity so we surface patients without overwhelming coordinators.

2

Pre-screen every referral before it reaches a site

Each patient is engaged through real human conversations and clinical review, including MADRS and similar scale validation, before any site referral. Sites conduct official screening and receive eligible, prepared, documentation-ready patients, not raw referral volume.

3

Deliver and de-risk continuously

We maintain backups against drop-off and patient attrition, and accelerate when timelines collapse. In competitive CNS landscapes, that continuity is how we carry the majority of enrollment and keep stalled studies moving.

CNS Results and Metrics

Head-to-head (adolescent schizophrenia, Phase 3, US)

Leapcure delivered 50% of all patients enrolled.

Head-to-head (bipolar, Phase 3, US, advocacy-only)

15 of the final 30 patients enrolled came from Leapcure.

Head-to-head (MDD sleep study, Phase 3, rural US sites with overnights)

15 of the final 20 patients enrolled came from Leapcure.

Speed and savings (Alzheimer's agitation, Phase 3)

Awareness campaigns engaged 6,000+ patients and contributed to a 30% enrollment increase (15/50) in four months, saving the client roughly $500K.

Reach and savings (ALS, Phase 3)

Global outreach across 10+ countries in North America, Europe, and Australia drove 30% of all enrollments and saved the client roughly $1.1M on a highly competitive study.

Speed (depression and insomnia, Phase 3)

Registered hundreds of patients and enrolled roughly 15 in a 1-2 week window against a planned four-month recruitment period.

Speed (sleep and mental-health device study, single site, Canada)

Hit the 90+ patient enrollment target in one week against an expected timeline of over two months. MedOps pre-screening validated patient MADRS scores.

Outperformance (MDD, Phase 3, ~3x)

Enrolled 40+ patients in roughly four months using a regional advocacy strategy adapted to site capacity plus precision digital including Reddit. Outperformed all other vendors by about 3x, doubled site-contacted rates, tripled screening and enrollment rates, and was the only source of enrollments at eight sites.

De-risking (Phase 1 CNS funnel)

1,228 referred, 1,040 reached, 85 assigned, 30 screened, 9 Leapcure enrollments (10% of total study enrollments), with 25-30 additional expected on need.

Ad effectiveness (2024 Meta global benchmarking on MDD ad effectiveness)

Leapcure effective spend 86.9% versus a 74.8% vertical benchmark and 58.2% for competitors. Real performance reaching high-intent CNS patients, not a schema claim.

Four channels. Built for CNS across psychiatry and neurology

Leapcure reaches CNS patients through trusted advocacy, pre-screens every referral with scale validation, delivers head-to-head when timelines collapse, and brings honest answer-engine visibility and proven ad effectiveness to your trial.

Channel 1: National mental-health and neurology advocacy depth

  • •We engage national mental-health and neurology advocacy partners, including Alzheimer's News Today, Alzheimer's Speaks, ALS News Today, the ALS Association Florida Chapter, the Anxiety and Depression Association of America, and Families for Depression Awareness.
  • •These are the communities CNS patients already trust, across both psychiatry and neurology.
  • •Partnerships are active and co-developed, not list buys. 40+ advocacy partnerships is our program standard, and we name only confirmed partners.

Channel 2: Pre-screening with scale validation and Patient Success

  • •Every referral is engaged through real human conversations and clinical review, including MADRS and similar scale validation, before it reaches a site.
  • •Patients arrive eligible, prepared, and documentation-ready, which lowers site burden and screen fails.
  • •On a sleep and mental-health study, MedOps pre-screening validated patient MADRS scores before referral.

Channel 3: Speed and head-to-head delivery

  • •We deliver when timelines collapse, from a 90+ patient target hit in one week to about 15 enrollments in a 1-2 week window against a four-month plan.
  • •We outperform other vendors head-to-head: on one Phase 3 MDD study, about 3x over all other vendors and the only enrollment source at eight sites.
  • •In competitive CNS landscapes, carrying the majority of enrollment is the difference between a study that finishes and one that stalls.

Channel 4: AEO, AI-search visibility, and ad effectiveness

  • •Patients increasingly ask ChatGPT, Perplexity, and Google's AI Overview which trials they may qualify for. We make your trial's information genuinely retrievable through crawlable, server-rendered content, first-party data with sourced stats, a named reviewer, and a last-updated date.
  • •Because AI engines cite trusted third-party sources more than any single brand domain, our presence in advocacy orgs and ClinicalTrials.gov is the structural advantage, not schema tricks or markup promises.
  • •On ad effectiveness, 2024 Meta global benchmarking on MDD put Leapcure at 86.9% effective spend versus a 74.8% vertical benchmark and 58.2% for competitors. Real performance reaching high-intent patients, not a schema claim.

National mental-health and neurology advocacy partners

Leapcure's partnerships are active and co-developed, not list buys. 40+ advocacy partnerships is the program standard, and we name only confirmed partners. On a Phase 3 MDD study, our advocacy strategy launched with NAMI NYC Metro, the Anxiety and Depression Association of America, The Stability Network, Families for Depression Awareness, the Mental Health Association of Central Florida, We Search Together, The Mighty, Hope for Mental Health, and Healthline.

Alzheimer's News Today

Patient-focused Alzheimer's news and community resource reaching patients and caregivers

Alzheimer's Speaks

Advocacy and awareness platform for the Alzheimer's and dementia community

Songs and Smiles

Music-based engagement organization serving older adults and the dementia community

Swedish Neuro Registries

Neurology registry network supporting research reach across the neurology community

ALS News Today

Patient-focused ALS news and community resource reaching patients and caregivers

ALS Association - Florida Chapter

Regional ALS patient organization and trusted referral channel in the ALS community

Anxiety and Depression Association of America

National advocacy organization for anxiety, depression, and related mood conditions

Families for Depression Awareness

Patient and caregiver organization focused on depression and mood disorders

Living with a CNS condition, or caring for someone who is? A clinical trial may be an option to explore.

If you are living with depression, bipolar disorder, schizophrenia, insomnia, Alzheimer's, ALS, or a related condition, or caring for someone who is, a clinical trial may be an option to explore alongside your existing care, never instead of it. We know these are hard, personal conditions, and we will never pressure you. Leapcure's team answers your questions honestly, explains what a trial involves, and supports you and your caregivers step by step.

Explore CNS trials and intake
Leapcure kangaroo mascot

Across 140+ studies and 40+ sponsors, Leapcure has averaged more than half of every site's enrollments since 2020. Our Phase 3 CNS wins cut timelines from months to weeks (90+ patients in one week, about 15 in a 1-2 week window), saved clients roughly $500K and $1.1M, and outperformed all other vendors on a Phase 3 depression study by about 3x. As one sponsor on a sleep and mental-health study told us, "You guys are great. Wow, what a great experience." Let's talk about your CNS program.

Talk to our CNS team